Review



pik3ca e545k coding sequence  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Addgene inc pik3ca e545k coding sequence
    (A) Experimental setup for PI3K inhibitor (PI3Ki) and MEK inhibitor (MEKi) treatment and release. (B) Protein levels of pERK1/2, ERK1/2, pAKT, and AKT after HRAS G12V induction and treatment with MEKi or PI3Ki. (C) S phase percentage after HRAS G12V induction with release from PI3Ki or MEKi as determined by EdU labelling and flow cytometry. N=4. (D) Nuclear EU intensity after HRAS G12V induction and release from MEKi or PI3Ki. N=5 (MEKi N=4). (E) Average replication fork speeds after HRAS G12V induction and release from MEKi or PI3Ki. N=4. (F) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after UCL-TRO-1938 treatment of uninduced BJ-hTERT-BRAF V600E cells for 48 h. (G) Nuclear EU intensity after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=4. (H) Median replication fork speeds after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=3. (I) Inducible expression of oncogenic PI3K <t>E545K</t> , alone or with KRAS G12V or BRAF V600E , was used to increase PI3K signalling, on its own or in combination with MAPK activation. (J) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after oncogene induction or doxycycline treatment (72 h) of parental cells (BJ-hTERT). (K) Nuclear EU intensity after oncogene induction. N=4. (EL) Median replication fork speeds after oncogene induction. N=4-6. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.
    Pik3ca E545k Coding Sequence, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pik3ca+e545k+coding+sequence/pCIG+PIK3CA+E545K+(Plasmid+%2373055)/bio_rxiv__64898__2026__03__16__711577-189-14-18
    Average 93 stars, based on 4 article reviews
    pik3ca e545k coding sequence - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress"

    Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress

    Journal: bioRxiv

    doi: 10.64898/2026.03.16.711577

    (A) Experimental setup for PI3K inhibitor (PI3Ki) and MEK inhibitor (MEKi) treatment and release. (B) Protein levels of pERK1/2, ERK1/2, pAKT, and AKT after HRAS G12V induction and treatment with MEKi or PI3Ki. (C) S phase percentage after HRAS G12V induction with release from PI3Ki or MEKi as determined by EdU labelling and flow cytometry. N=4. (D) Nuclear EU intensity after HRAS G12V induction and release from MEKi or PI3Ki. N=5 (MEKi N=4). (E) Average replication fork speeds after HRAS G12V induction and release from MEKi or PI3Ki. N=4. (F) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after UCL-TRO-1938 treatment of uninduced BJ-hTERT-BRAF V600E cells for 48 h. (G) Nuclear EU intensity after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=4. (H) Median replication fork speeds after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=3. (I) Inducible expression of oncogenic PI3K E545K , alone or with KRAS G12V or BRAF V600E , was used to increase PI3K signalling, on its own or in combination with MAPK activation. (J) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after oncogene induction or doxycycline treatment (72 h) of parental cells (BJ-hTERT). (K) Nuclear EU intensity after oncogene induction. N=4. (EL) Median replication fork speeds after oncogene induction. N=4-6. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.
    Figure Legend Snippet: (A) Experimental setup for PI3K inhibitor (PI3Ki) and MEK inhibitor (MEKi) treatment and release. (B) Protein levels of pERK1/2, ERK1/2, pAKT, and AKT after HRAS G12V induction and treatment with MEKi or PI3Ki. (C) S phase percentage after HRAS G12V induction with release from PI3Ki or MEKi as determined by EdU labelling and flow cytometry. N=4. (D) Nuclear EU intensity after HRAS G12V induction and release from MEKi or PI3Ki. N=5 (MEKi N=4). (E) Average replication fork speeds after HRAS G12V induction and release from MEKi or PI3Ki. N=4. (F) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after UCL-TRO-1938 treatment of uninduced BJ-hTERT-BRAF V600E cells for 48 h. (G) Nuclear EU intensity after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=4. (H) Median replication fork speeds after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=3. (I) Inducible expression of oncogenic PI3K E545K , alone or with KRAS G12V or BRAF V600E , was used to increase PI3K signalling, on its own or in combination with MAPK activation. (J) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after oncogene induction or doxycycline treatment (72 h) of parental cells (BJ-hTERT). (K) Nuclear EU intensity after oncogene induction. N=4. (EL) Median replication fork speeds after oncogene induction. N=4-6. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.

    Techniques Used: Flow Cytometry, Expressing, Activation Assay

    Related Articles

    Mutagenesis:

    Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress
    Article Snippet: Mutant BRAF (V600E) was synthesised by GenScript and cloned a doxycycline-inducible mutant pLIX403-ccdB-Blast (Addgene, Plasmid #158560) using gateway cloning. .. A doxycycline-inducible mutant PIK3CA E545K expression vector was created by PCR subcloning of the PIK3CA E545K coding sequence (Addgene, Plasmid #73055) into a modified pTRIPZ vector (Addgene, Plasmid #206981) lacking the TurboGFP coding sequence. .. KRAS G12V vector was purchased from (Addgene, #35635).

    Expressing:

    Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress
    Article Snippet: Mutant BRAF (V600E) was synthesised by GenScript and cloned a doxycycline-inducible mutant pLIX403-ccdB-Blast (Addgene, Plasmid #158560) using gateway cloning. .. A doxycycline-inducible mutant PIK3CA E545K expression vector was created by PCR subcloning of the PIK3CA E545K coding sequence (Addgene, Plasmid #73055) into a modified pTRIPZ vector (Addgene, Plasmid #206981) lacking the TurboGFP coding sequence. .. KRAS G12V vector was purchased from (Addgene, #35635).

    Polymerase Chain Reaction:

    Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress
    Article Snippet: Mutant BRAF (V600E) was synthesised by GenScript and cloned a doxycycline-inducible mutant pLIX403-ccdB-Blast (Addgene, Plasmid #158560) using gateway cloning. .. A doxycycline-inducible mutant PIK3CA E545K expression vector was created by PCR subcloning of the PIK3CA E545K coding sequence (Addgene, Plasmid #73055) into a modified pTRIPZ vector (Addgene, Plasmid #206981) lacking the TurboGFP coding sequence. .. KRAS G12V vector was purchased from (Addgene, #35635).

    Subcloning:

    Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress
    Article Snippet: Mutant BRAF (V600E) was synthesised by GenScript and cloned a doxycycline-inducible mutant pLIX403-ccdB-Blast (Addgene, Plasmid #158560) using gateway cloning. .. A doxycycline-inducible mutant PIK3CA E545K expression vector was created by PCR subcloning of the PIK3CA E545K coding sequence (Addgene, Plasmid #73055) into a modified pTRIPZ vector (Addgene, Plasmid #206981) lacking the TurboGFP coding sequence. .. KRAS G12V vector was purchased from (Addgene, #35635).

    Sequencing:

    Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress
    Article Snippet: Mutant BRAF (V600E) was synthesised by GenScript and cloned a doxycycline-inducible mutant pLIX403-ccdB-Blast (Addgene, Plasmid #158560) using gateway cloning. .. A doxycycline-inducible mutant PIK3CA E545K expression vector was created by PCR subcloning of the PIK3CA E545K coding sequence (Addgene, Plasmid #73055) into a modified pTRIPZ vector (Addgene, Plasmid #206981) lacking the TurboGFP coding sequence. .. KRAS G12V vector was purchased from (Addgene, #35635).

    Plasmid Preparation:

    Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress
    Article Snippet: Mutant BRAF (V600E) was synthesised by GenScript and cloned a doxycycline-inducible mutant pLIX403-ccdB-Blast (Addgene, Plasmid #158560) using gateway cloning. .. A doxycycline-inducible mutant PIK3CA E545K expression vector was created by PCR subcloning of the PIK3CA E545K coding sequence (Addgene, Plasmid #73055) into a modified pTRIPZ vector (Addgene, Plasmid #206981) lacking the TurboGFP coding sequence. .. KRAS G12V vector was purchased from (Addgene, #35635).

    Modification:

    Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress
    Article Snippet: Mutant BRAF (V600E) was synthesised by GenScript and cloned a doxycycline-inducible mutant pLIX403-ccdB-Blast (Addgene, Plasmid #158560) using gateway cloning. .. A doxycycline-inducible mutant PIK3CA E545K expression vector was created by PCR subcloning of the PIK3CA E545K coding sequence (Addgene, Plasmid #73055) into a modified pTRIPZ vector (Addgene, Plasmid #206981) lacking the TurboGFP coding sequence. .. KRAS G12V vector was purchased from (Addgene, #35635).



    Similar Products

    pik3ca e545k coding sequence  (Addgene inc)
    93
    Addgene inc pik3ca e545k coding sequence
    (A) Experimental setup for PI3K inhibitor (PI3Ki) and MEK inhibitor (MEKi) treatment and release. (B) Protein levels of pERK1/2, ERK1/2, pAKT, and AKT after HRAS G12V induction and treatment with MEKi or PI3Ki. (C) S phase percentage after HRAS G12V induction with release from PI3Ki or MEKi as determined by EdU labelling and flow cytometry. N=4. (D) Nuclear EU intensity after HRAS G12V induction and release from MEKi or PI3Ki. N=5 (MEKi N=4). (E) Average replication fork speeds after HRAS G12V induction and release from MEKi or PI3Ki. N=4. (F) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after UCL-TRO-1938 treatment of uninduced BJ-hTERT-BRAF V600E cells for 48 h. (G) Nuclear EU intensity after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=4. (H) Median replication fork speeds after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=3. (I) Inducible expression of oncogenic PI3K <t>E545K</t> , alone or with KRAS G12V or BRAF V600E , was used to increase PI3K signalling, on its own or in combination with MAPK activation. (J) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after oncogene induction or doxycycline treatment (72 h) of parental cells (BJ-hTERT). (K) Nuclear EU intensity after oncogene induction. N=4. (EL) Median replication fork speeds after oncogene induction. N=4-6. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.
    Pik3ca E545k Coding Sequence, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pik3ca+e545k+coding+sequence/pCIG+PIK3CA+E545K+(Plasmid+%2373055)/bio_rxiv__64898__2026__03__16__711577-189-14-18
    Average 93 stars, based on 1 article reviews
    pik3ca e545k coding sequence - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Experimental setup for PI3K inhibitor (PI3Ki) and MEK inhibitor (MEKi) treatment and release. (B) Protein levels of pERK1/2, ERK1/2, pAKT, and AKT after HRAS G12V induction and treatment with MEKi or PI3Ki. (C) S phase percentage after HRAS G12V induction with release from PI3Ki or MEKi as determined by EdU labelling and flow cytometry. N=4. (D) Nuclear EU intensity after HRAS G12V induction and release from MEKi or PI3Ki. N=5 (MEKi N=4). (E) Average replication fork speeds after HRAS G12V induction and release from MEKi or PI3Ki. N=4. (F) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after UCL-TRO-1938 treatment of uninduced BJ-hTERT-BRAF V600E cells for 48 h. (G) Nuclear EU intensity after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=4. (H) Median replication fork speeds after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=3. (I) Inducible expression of oncogenic PI3K E545K , alone or with KRAS G12V or BRAF V600E , was used to increase PI3K signalling, on its own or in combination with MAPK activation. (J) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after oncogene induction or doxycycline treatment (72 h) of parental cells (BJ-hTERT). (K) Nuclear EU intensity after oncogene induction. N=4. (EL) Median replication fork speeds after oncogene induction. N=4-6. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.

    Journal: bioRxiv

    Article Title: PI3K-AKT activation determines oncogenic RAS-induced hypertranscription and replication stress

    doi: 10.64898/2026.03.16.711577

    Figure Lengend Snippet: (A) Experimental setup for PI3K inhibitor (PI3Ki) and MEK inhibitor (MEKi) treatment and release. (B) Protein levels of pERK1/2, ERK1/2, pAKT, and AKT after HRAS G12V induction and treatment with MEKi or PI3Ki. (C) S phase percentage after HRAS G12V induction with release from PI3Ki or MEKi as determined by EdU labelling and flow cytometry. N=4. (D) Nuclear EU intensity after HRAS G12V induction and release from MEKi or PI3Ki. N=5 (MEKi N=4). (E) Average replication fork speeds after HRAS G12V induction and release from MEKi or PI3Ki. N=4. (F) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after UCL-TRO-1938 treatment of uninduced BJ-hTERT-BRAF V600E cells for 48 h. (G) Nuclear EU intensity after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=4. (H) Median replication fork speeds after KRAS G12V induction +/- UCL-TRO-1938 (5 μM) for 48 h. N=3. (I) Inducible expression of oncogenic PI3K E545K , alone or with KRAS G12V or BRAF V600E , was used to increase PI3K signalling, on its own or in combination with MAPK activation. (J) Protein levels of pAKT (S473), AKT, pERK1/2 and ERK1/2 after oncogene induction or doxycycline treatment (72 h) of parental cells (BJ-hTERT). (K) Nuclear EU intensity after oncogene induction. N=4. (EL) Median replication fork speeds after oncogene induction. N=4-6. Means +/-SEM (bars) are shown with 2-way ANOVA or mixed effects analysis.

    Article Snippet: A doxycycline-inducible mutant PIK3CA E545K expression vector was created by PCR subcloning of the PIK3CA E545K coding sequence (Addgene, Plasmid #73055) into a modified pTRIPZ vector (Addgene, Plasmid #206981) lacking the TurboGFP coding sequence.

    Techniques: Flow Cytometry, Expressing, Activation Assay